See more : MasterBrand, Inc. (MBC) Income Statement Analysis – Financial Results
Complete financial analysis of Invitae Corporation (NVTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Invitae Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Harte Hanks, Inc. (HRTH) Income Statement Analysis – Financial Results
- Challenger Limited (CGF.AX) Income Statement Analysis – Financial Results
- ICTS International N.V. (ICTSF) Income Statement Analysis – Financial Results
- KDDI Corporation (KDDIF) Income Statement Analysis – Financial Results
- Japan Gold Corp. (JG.V) Income Statement Analysis – Financial Results
Invitae Corporation (NVTA)
About Invitae Corporation
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 516.30M | 460.45M | 279.60M | 216.82M | 147.70M | 68.22M | 25.05M | 8.38M | 1.60M | 148.00K | 0.00 |
| Cost of Revenue | 417.26M | 348.67M | 198.28M | 118.10M | 80.11M | 50.14M | 27.88M | 16.52M | 5.62M | 667.00K | 0.00 |
| Gross Profit | 99.05M | 111.78M | 81.32M | 98.72M | 67.59M | 18.08M | -2.83M | -8.15M | -4.02M | -519.00K | 0.00 |
| Gross Profit Ratio | 19.18% | 24.28% | 29.09% | 45.53% | 45.76% | 26.50% | -11.30% | -97.22% | -250.62% | -350.68% | 0.00% |
| Research & Development | 402.09M | 416.09M | 240.61M | 141.53M | 63.50M | 46.47M | 44.63M | 42.81M | 22.14M | 16.04M | 5.56M |
| General & Administrative | 192.31M | 248.07M | 324.57M | 79.07M | 52.23M | 39.47M | 24.09M | 16.05M | 12.61M | 5.76M | 3.00M |
| Selling & Marketing | 218.88M | 225.91M | 168.32M | 122.24M | 74.43M | 53.42M | 28.64M | 22.48M | 8.76M | 2.43M | 0.00 |
| SG&A | 411.20M | 473.98M | 492.89M | 201.31M | 126.66M | 92.89M | 52.72M | 38.53M | 21.37M | 8.20M | 3.00M |
| Other Expenses | 8.05M | 25.68M | -32.33M | -3.89M | -2.57M | -303.00K | 348.00K | -94.00K | -79.00K | -26.00K | 2.00K |
| Operating Expenses | 813.28M | 890.07M | 733.50M | 342.83M | 190.15M | 139.36M | 97.35M | 81.33M | 43.51M | 24.23M | 8.56M |
| Cost & Expenses | 1.23B | 1.24B | 931.77M | 460.94M | 270.26M | 189.50M | 125.23M | 97.86M | 49.13M | 24.90M | 8.56M |
| Interest Income | 56.75M | 49.90M | 29.77M | 12.41M | 0.00 | 0.00 | 0.00 | 211.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 56.75M | 49.90M | 29.77M | 12.41M | 7.03M | 3.65M | 421.00K | 0.00 | 61.00K | 59.00K | 43.00K |
| Depreciation & Amortization | 150.13M | 106.15M | 6.72M | 12.32M | 13.54M | 9.18M | 6.55M | 5.32M | 2.32M | 928.00K | 277.00K |
| EBITDA | -3.12B | -391.64M | -652.17M | -244.11M | -111.59M | -121.58M | -93.63M | -89.48M | -45.19M | -23.85M | -8.28M |
| EBITDA Ratio | -109.26% | -145.97% | -230.85% | -106.91% | -75.55% | -178.22% | -398.57% | -1,068.00% | -2,968.02% | -16,115.54% | 0.00% |
| Operating Income | -714.24M | -778.29M | -652.17M | -244.11M | -122.56M | -121.28M | -100.18M | -89.48M | -47.53M | -24.75M | -8.56M |
| Operating Income Ratio | -138.34% | -169.03% | -233.25% | -112.59% | -82.98% | -177.77% | -399.96% | -1,068.00% | -2,963.09% | -16,725.00% | 0.00% |
| Total Other Income/Expenses | -2.44B | 362.42M | -62.10M | -16.30M | -9.60M | -3.96M | -73.00K | -305.00K | 36.00K | -85.00K | -41.00K |
| Income Before Tax | -3.15B | -415.86M | -714.27M | -260.42M | -132.16M | -125.24M | -100.26M | -89.78M | -47.67M | -24.84M | -8.60M |
| Income Before Tax Ratio | -610.34% | -90.32% | -255.46% | -120.10% | -89.48% | -183.57% | -400.26% | -1,071.64% | -2,971.82% | -16,782.43% | 0.00% |
| Income Tax Expense | -44.90M | -36.86M | -105.40M | -18.45M | -2.80M | -1.86M | -5.78M | -5.11M | -2.33M | 33.00K | 45.00K |
| Net Income | -3.11B | -379.01M | -608.87M | -241.97M | -129.36M | -123.38M | -100.26M | -89.78M | -47.67M | -24.84M | -8.60M |
| Net Income Ratio | -601.64% | -82.31% | -217.77% | -111.60% | -87.58% | -180.85% | -400.26% | -1,071.64% | -2,971.82% | -16,782.43% | 0.00% |
| EPS | -13.18 | -1.80 | -4.52 | -2.66 | -1.94 | -2.65 | -3.02 | -3.18 | -1.60 | -1.67 | -0.58 |
| EPS Diluted | -13.18 | -1.80 | -4.52 | -2.66 | -1.94 | -2.65 | -3.02 | -3.18 | -1.60 | -1.67 | -0.58 |
| Weighted Avg Shares Out | 235.68M | 210.95M | 134.59M | 90.86M | 66.75M | 46.51M | 33.18M | 28.21M | 29.80M | 14.88M | 14.88M |
| Weighted Avg Shares Out (Dil) | 235.68M | 210.95M | 134.59M | 90.86M | 66.75M | 46.51M | 33.18M | 28.21M | 29.80M | 14.88M | 14.88M |
Why Invitae Stock Was So Healthy This Week
Even though the genetics testing specialist didn't divulge the financial details of a new partnership, investors nevertheless were happpy about the news.
Is Invitae Stock a Buy Now?
Shares have dropped more than 80% this year.
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research
– Using Invitae's Ciitizen patient-driven data platform, AstraZeneca and the Cholangiocarcinoma Foundation will access lived experience of patients with a rare cancer to drive further research – – Real-world insights will be translated into cholangiocarcinoma treatment patterns and outcomes in...
Why Invitae Corporation Sank as Much as 25.5% This Week
Broad market movements, unprofitability, and high short interest seem to be hitting Invitae stock this week.
Invitae Busted Business Model Offers A Tactical Opportunity
NVTA's business model remains untested, having spent the past decade building a precarious market position with artificially low pricing strategies. Under its turnaround plan, management cut a third of the workforce, which bodes favorably for Q3 EPS and cash flows...
Why Shares of Invitae Dropped 13% on Tuesday
A day after a nice climb, investors unloaded shares of the medical genetic testing stock.
NVTA Stock Alert: Invitae Announces Data-Sharing Partnership With Simons Searchlight
Source: Chepko Danil Vitalevich / Shutterstock.com Invitae (NYSE: NVTA ) stock is in the spotlight today after the company announced a collaboration with Simons Searchlight. Simons is an international research program that focuses on rare genetic neurodevelopmental disorders.
Invitae to Present at Upcoming Investor Conference
SAN FRANCISCO , Aug. 30, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in the following investor conference: Morgan Stanley 20th Annual Global Healthcare Conference – Fireside chat...
9 Key Meme Stocks To Run Out Of Money In Less Than 2 Years
If you think investing in "meme stocks" is like playing a game of musical chairs, you might be surprised at how quickly the music might stop. The post 9 Key Meme Stocks To Run Out Of Money In Less Than...
Invitae Stock Won't Be Tripling Again Any Time Soon
Invitae (NYSE: NVTA ) stock popped on investors' radars earlier this month thanks to its nearly 277% surge in price on Aug 10. Following its latest earnings report, retail traders jumped into the stock as well.
Source: https://incomestatements.info
Category: Stock Reports